Evidence map›Paper›PMID 42878173›Full record

ArticleGut microbes2026

BiotaPredictor: A machine learning framework for predicting drug depletion by the human gut microbiota.

Benyamin Naranjani, Laura E McCoubrey, Anders Borde, Gustaf Hulthe, Mats Josefson, Susanna Abrahmsén-Alami, Bertil Abrahamsson, Abdul W Basit

Abstract read
In one paragraph

Article in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Benyamin NaranjaniDepartment of Pharmacy, Uppsala Biomedical Center, Uppsala University, Uppsala, Sweden.
Laura E McCoubreyUCL School of Pharmacy, University College London, London, UK.
Anders BordeGlobal Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden.
Gustaf HultheGlobal Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden.
Mats JosefsonGlobal Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden.
Susanna Abrahmsén-AlamiGlobal Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden.ORCID 0000-0003-2696-090X
Bertil AbrahamssonGlobal Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden.
Abdul W BasitUCL School of Pharmacy, University College London, London, UK.ORCID 0000-0002-5368-6603

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gut microbiota can profoundly influence the performance of oral medicines by metabolizing or bioaccumulating drugs, thereby reducing systemic exposure and contributing to variable patient responses. Despite growing recognition of these interactions, microbiota-driven drug depletion remains insufficiently addressed during early development. Here, we present BiotaPredictor, a freely accessible web-based machine learning platform that predicts the likelihood of drug depletion by human intestinal microbiota from molecular structure. We compiled two curated datasets containing microbial depletion outcomes: (i) a consistently annotated AstraZeneca dataset (158 compounds) and (ii) an expanded integrated dataset incorporating published evidence (522 compounds). Multiple molecular descriptors-including physicochemical properties, 3D conformational features, and fingerprint-based encodings-were evaluated across a suite of classification algorithms. A logistic regression model trained on the AstraZeneca dataset using physicochemical parameters achieved the highest performance, correctly classifying all compounds in an external validation study (3 depleted, 9 stable). BiotaPredictor enables early triage of compounds susceptible to microbiota-mediated loss and can inform lead optimization, formulation strategy, and pharmacokinetic prediction. Integrating microbiota liability assessment into development pipelines will contribute to safer, more efficacious drug products and support precision delivery of orally administered therapeutics.

Indexed as

Gastrointestinal MicrobiomeMachine LearningBacteriaHumansPharmaceutical PreparationsPredictive Learning ModelsPharmaceutical Preparationsartificial intelligencebiotransformation of medicationsdrug metabolism and bioaccumulationgastrointestinal microbiomeOral drug deliverypharmacomicrobiomics

Identifiers

PMID42878173
PMCPMC13679337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.